Oncology最新文献

{"title":"Regorafenib Combination Therapy in Advanced Hepatocellular Carcinoma: With or without Transarterial Chemoembolization.","authors":"Lei Cao, Xiangyu Lu, Haoqing Chen, Xiang Yu, Jinze Li, Yi Peng, Lu Gu, Ji Feng, Ping Xie, Yaben Liu","doi":"10.1159/000542775","DOIUrl":"10.1159/000542775","url":null,"abstract":"<p><strong>Introduction: </strong>The effectiveness and tolerability of triple therapy, which combines regorafenib, a programmed death 1 (PD-1) inhibitor, and transarterial chemoembolization (TACE), were compared to dual therapy consisting of regorafenib and a PD-1 inhibitor in patients with advanced hepatocellular carcinoma (HCC).</p><p><strong>Methods: </strong>A retrospective analysis was conducted on patients with advanced HCC who underwent second-line therapy from March 2019 to June 2022 at multiple centers. Patients were stratified into two groups: dual therapy (comprising regorafenib and a PD-1 inhibitor) and triple therapy (consisting of regorafenib, a PD-1 inhibitor, and TACE). Propensity score matching (PSM) was used to control for potential confounding variables.</p><p><strong>Results: </strong>After PSM, 112 eligible patients were included, with 56 in the triple therapy group and 56 in the dual therapy group. Median overall survival (OS) was significantly longer in the triple therapy group (15.4 vs. 8.9 months, p < 0.001), as was median progression-free survival (6.8 vs. 3.3 months, p < 0.001). The objective response rate (37.5% vs. 5.4%, p < 0.001) and disease control rate (73.2% vs. 44.6%, p = 0.002) were significantly higher in the triple therapy group compared to the dual therapy group. The incidence and severity of adverse events were similar between the two groups.</p><p><strong>Conclusion: </strong>Triple therapy demonstrated superior survival benefits compared to dual therapy in patients with advanced HCC. Additionally, the safety profiles of the two treatment regimens were comparable.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-14"},"PeriodicalIF":2.5,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142739987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Digitalization and Standardization Oncology Drug Therapy Plans with the Onkopti Database for Online Publication and Import into Software.","authors":"Hartmut Link, Axel Wickenkamp, Annika Dresel, Migle Link, Cornelia Sibylle Link-Rachner, Rolf Hendrik van Lengen","doi":"10.1159/000542451","DOIUrl":"10.1159/000542451","url":null,"abstract":"<p><strong>Background: </strong>Oncological therapy is based on multidimensional therapy protocols. The requirements for standardized protocols and digitation are high. These protocols are created through several complex development stages to ensure standardized recording. The process involves analyzing original publications published in international journals and extracting key content. Standardized supportive therapy is then added, and compatibility with current guidelines and quality controls is checked.</p><p><strong>Summary: </strong>The Onkopti® website is based on the WordPress content management system and provides protocols in a variety of formats, generated through the use of a relational SQL database (<ext-link ext-link-type=\"uri\" xlink:href=\"http://www.onkopti.de\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">www.onkopti.de</ext-link>, <ext-link ext-link-type=\"uri\" xlink:href=\"http://www.onkopti.com\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">www.onkopti.com</ext-link>, <ext-link ext-link-type=\"uri\" xlink:href=\"http://www.oncopti.com\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">www.oncopti.com</ext-link>). It is continuously updated to include new therapeutic developments or changes to standard therapy. The protocols are stored in a relational database and can be exported to various application systems via a standardized XML format or other formats. The website and protocols are available in both German and English. As of January, 2025, there are over 2,700 protocols for parenteral and oral therapies for all oncological specialties.</p><p><strong>Key messages: </strong>The digitalization of protocol selection, prescription, pharmacy preparation, hospital or practice information system documentation, billing, and prescription creation can accelerate, standardize, and streamline these processes. This optimization can significantly reduce personnel costs, resulting in cost savings, and improved quality.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-14"},"PeriodicalIF":2.5,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142739945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concomitant Use of Proton Pump Inhibitors and CDK4/6 Inhibitors in Metastatic Hormone-Positive Breast Cancer: A Real-World Cohort Study.","authors":"Ogur Karhan, Serdar İleri, Zuhat Urakçı, Hayati Arvas, Delyadıl Karakaş Kılıç, Yasin Sezgin, Berrak Merit Erçek, Sezai Tunç","doi":"10.1159/000542693","DOIUrl":"10.1159/000542693","url":null,"abstract":"<p><strong>Introduction: </strong>Conflicting evidence exists regarding the concurrent use of cyclin-dependent kinase (CDK) 4/6 inhibitors and proton pump inhibitors (PPIs) in the treatment of breast cancer. This study aimed to investigate whether PPI use interferes with the efficacy of CDK4/6 inhibitors.</p><p><strong>Methods: </strong>This retrospective, multicenter, real-world study included 205 patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Patient data were collected from January 2020 to August 2023. Patients who received either ribociclib or palbociclib, with or without a PPI, were included. Median progression-free survival (mPFS) was estimated using the Kaplan-Meier method, and factors associated with mPFS were analyzed using Cox regression.</p><p><strong>Results: </strong>Among the patients, 100 received palbociclib and 105 received ribociclib. In the palbociclib group, 40 patients (40%) used a PPI, and 60 (60%) did not. The mPFS was 16.1 months for patients with a PPI versus 22.2 months for those without (p = 0.26). In the ribociclib group, 44 patients used a PPI and 61 did not use a PPI. The median PFS was comparable between patients receiving PPIs and those not receiving PPIs (19.3 months and 20.7 months, respectively). Poor PFS was associated with liver metastasis, brain metastasis, and high Ki-67.</p><p><strong>Conclusion: </strong>Concomitant use of PPIs with ribociclib or palbociclib did not affect the efficacy of either CDK4/6 inhibitor. PPIs can be administered alongside these medications when clinically indicated.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-10"},"PeriodicalIF":2.5,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142716714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metastatic Patterns: Insights from Japanese Pathological Autopsy Registry Analysis.","authors":"Tomohiko Hara, Suguru Oka, Shinji Ito, Takeshi Yamaguchi, Michikata Hayashida, Kazushige Sakaguchi, Shinji Urakami","doi":"10.1159/000542684","DOIUrl":"10.1159/000542684","url":null,"abstract":"<p><strong>Introduction: </strong>Understanding the metastatic patterns is crucial for the treatment of malignancies. This study aimed to identify the characteristic organ metastases of primary malignancies, including rare malignancies, and classify them according to their metastatic patterns.</p><p><strong>Methods: </strong>We extracted data on primary malignancies and organ metastases from the Annual of Pathological Autopsy Cases in Japan recorded in 1993-2021. Autopsy findings of the primary and metastatic organs in patients with malignancy were recorded on an organ-by-organ basis. The metastatic frequency (number of metastases per autopsy) and the proportion (percentage of organs with metastases out of the total in a primary malignancy) for 48 organ metastasis sites across 76 primary malignancies were calculated. Metastatic patterns were classified into hierarchical and nonhierarchical clustering classifications based on the standard proportion of organ metastases.</p><p><strong>Results: </strong>A total of 332,195 autopsy cases and 810,206 organ metastases were analyzed. The metastatic frequency of all malignancies was 2.44. Malignancies of the placenta, eye, and ovary showed a higher propensity for metastasis, whereas central nervous system malignancies showed a lower tendency. Metastasis site was a characteristic of each malignancy, with a particularly high proportion of lung metastasis in parathyroid malignancy and bone metastasis in prostate malignancy. In the hierarchical and nonhierarchical cluster methods, brain, lung, liver, bone, peritoneum, and hematolymphoid organ were key metastatic sites, and this factor divided primary malignancies into seven categories. The unweighted kappa coefficient comparing the two classification methods was 0.84 (95% confidence interval: 0.75-0.93). The proportion of metastatic organs was influenced by anatomical location and/or organ specificity of the primary malignancies.</p><p><strong>Conclusion: </strong>Our study provides a comprehensive overview of the patterns and frequencies of metastatic organ sites associated with 76 primary malignancies. Our findings will provide useful information for future research and clinical practice.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-12"},"PeriodicalIF":2.5,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142687612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Index Based on Inflammatory Markers Correlates with Treatment Efficacy of Nivolumab for Recurrent/Metastatic Head and Neck Cancer.","authors":"Hiroe Tada, Reika Kawabata-Iwakawa, Hideyuki Takahashi, Kazuaki Chikamatsu","doi":"10.1159/000542683","DOIUrl":"10.1159/000542683","url":null,"abstract":"<p><strong>Introduction: </strong>Immune checkpoint inhibitors provide new treatments for patients with recurrent or metastatic (R/M) head and neck cancers. Herein, we focused on systemic inflammatory markers in peripheral blood, including blood cell fractions, albumin (Alb), and C-reactive protein, and determined their association with nivolumab treatment response. We also examined the potential application of inflammatory markers as prognostic tools.</p><p><strong>Methods: </strong>We assessed pretreatment systemic inflammatory markers in 61 patients with R/M head and neck cancer treated with nivolumab, determining their association with treatment response using Kaplan-Meier, multivariate, and regression analyses. Using flow cytometry, we investigated circulating T-cell subsets in 36 patients with R/M head and neck cancer. Finally, we examined the correlation between each statistically analyzed parameter and peripheral circulating T-cell activation.</p><p><strong>Results: </strong>Systemic inflammatory marker values were used to estimate overall survival (OS) time by performing multivariate analysis. Systemic inflammatory markers were assigned importance for each coefficient. Monocyte and lymphocyte counts strongly impacted OS. Indices dependent on white blood cell and monocyte counts, lymphocyte percentage, platelet count, Alb levels, and prognostic nutrition index were useful prognostic tools in the regression analysis. The simplest prognostic index was defined as white blood cells (103/μL) +2 × lymphocyte percentage (%) +12 × number of monocytes (103/μL) + 27 × serum Alb. A high index that was significantly associated with a better prognosis negatively correlated with CD38/CD8 and ki67/CD8 percentages.</p><p><strong>Conclusions: </strong>According to the findings of the present study, systemic inflammatory markers may help predict the prognosis, activation, and exhaustion of circulating T cells. In patients with R/M head and neck cancer treated with nivolumab, systemic inflammatory markers could provide new insights into rational strategies in cancer immunotherapy for R/M head and neck cancer.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-11"},"PeriodicalIF":2.5,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142682229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Association between Body Mass Index and Mortality in Breast Cancer Patients Receiving Pembrolizumab.","authors":"Cho-Han Chiang, Xiaocao Xu, Ahmed Shahid, Junmin Song, Kuan-Yu Chi, Yu-Cheng Chang, Yu Chang, Cho-Hung Chiang, Shuwen Lin","doi":"10.1159/000542542","DOIUrl":"10.1159/000542542","url":null,"abstract":"<p><strong>Introduction: </strong>A higher body mass index (BMI) has been associated with a better response and overall survival in patients with lung cancer or melanoma receiving immune checkpoint inhibitors (ICIs). Pembrolizumab has been approved for the use of breast cancer, but its relationship with BMI on survival outcomes is unclear.</p><p><strong>Methods: </strong>We conducted a retrospective, propensity score-matched cohort study using the TriNetX Analytics Network database, which contains de-identified data from over 120 participating healthcare institutions. We included all adult female patients with breast cancer who received pembrolizumab. We excluded patients who were prescribed endocrine or human epidermal growth factor receptor 2-targeted therapies. We compared the 1-year all-cause mortality between patients who were overweight or obese (BMI ≥25 kg/m2) and those who were normal weight (BMI <25 kg/m2). We matched patients on predetermined variables including age, race, breast cancer-directed therapy, cardiovascular and diabetes medications, and underlying comorbidities.</p><p><strong>Results: </strong>We identified 1,628 eligible patients, of whom 1,163 had a BMI ≥25 kg/m2 and 465 had a BMI <25 kg/m2. After propensity score matching, 410 patients in each cohort were well balanced for demographics, breast cancer-directed therapy, and underlying comorbidities. The mean ages for patients with BMI ≥25 kg/m2 and BMI <25 kg/m2 were 56.7 ± 14.0 and 56.9 ± 15.0, respectively. Over a median follow-up of 1 year, 28 and 53 patients died in the BMI ≥25 kg/m2 and BMI <25 kg/m2 cohorts, respectively. Patients with BMI ≥25 kg/m2 had a 49% lower risk of all-cause mortality compared with those with BMI <25 kg/m2 (hazard ratio, 0.51 [95% CI: 0.33-0.81]).</p><p><strong>Conclusions: </strong>A BMI ≥25 kg/m2 was associated with a lower all-cause mortality among breast cancer patients receiving pembrolizumab.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-5"},"PeriodicalIF":2.5,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142625256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-Line Durvalumab plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice.","authors":"Yasutoshi Fujii, Tomokazu Kawaoka, Yuki Shirane, Ryoichi Miura, Hikaru Nakahara, Kenji Yamaoka, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Daiki Miki, Nelson Clair Hayes, Masataka Tsuge, Yuko Nakamura, Kazuo Awai, Shiro Oka","doi":"10.1159/000542517","DOIUrl":"10.1159/000542517","url":null,"abstract":"<p><strong>Introduction: </strong>Durvalumab plus tremelimumab combination therapy (STRIDE regimen) is a new first-line option for unresectable hepatocellular carcinoma (uHCC), but little real-world data are available to determine which patients are most likely to respond.</p><p><strong>Methods: </strong>This study retrospectively evaluated patients with uHCC who were treated with the STRIDE regimen as the 1st line at our hospital. The primary endpoint of the study was the objective response rate (ORR). We focused on identifying factors associated with cases that had a favorable response.</p><p><strong>Results: </strong>Twenty-one patients were included. In best response, there were 11 partial response cases, with an ORR of 52.4%. Median progression-free survival was 6.8 months, and overall survival did not reach the median time. A high tumor-to-liver ratio of the maximum value of the standardized uptake value (TLR) on baseline fluorodeoxyglucose positron emission tomography (FDG-PET) was associated with response, while TLRs were significantly higher in poorly differentiated uHCC.</p><p><strong>Conclusion: </strong>The STRIDE regimen may be beneficial for systemic therapy-naive uHCC patients. High TLR on baseline FDG-PET could be a potentially useful biomarker for response.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-6"},"PeriodicalIF":2.5,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142625236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Potential of ESCO2 as a Prognostic and Immunotherapeutic Marker of Pan-Cancer and Its Role in Anti-PD-1 Treatment of Bladder Cancer.","authors":"Wei Guo, Shuo Zhao, Keqiang Yan, Yidong Fan, Jikai Liu","doi":"10.1159/000542188","DOIUrl":"10.1159/000542188","url":null,"abstract":"<p><strong>Introduction: </strong>Establishment of sister chromatid cohesion N-acetyltransferase 2 (ESCO2), a member of the EFO2 family, is implicated in the pathogenesis and progression of various cancers. However, there has been limited comprehensive pan-cancer analysis conducted on ESCO2 thus far.</p><p><strong>Methods: </strong>Publicly available databases, such as the UCSC Xena database, were utilized to examine differential expression patterns across various cancer types. In addition, variations in expression levels were investigated across distinct clinical stages. Univariate Cox regression and Kaplan-Meier survival analyses were conducted to evaluate the impact on overall survival (OS), disease-specific survival (DSS), disease-free interval (DFI), and progression-free interval (PFI) at the pan-cancer level. The correlation between ESCO2 expression and immune cell infiltration was examined to gain insight into the tumor microenvironment (TME) in different cancers. The results of the bioinformatic analysis were validated using immunotherapy clinical trials and pathological specimens. CCK-8 and Transwell assay experiments were performed to investigate the biological function of ESCO2.</p><p><strong>Results: </strong>ESCO2 expression was found to be upregulated in most cancers, with a correlation to TNM stages. Prognostic analysis indicated that overexpression of ESCO2 was associated with poor prognosis in various cancers. Furthermore, the correlation between ESCO2 expression and immune cell infiltration suggested its potential as a predictor for immunotherapy efficacy. Notably, ESCO2 expression showed positive associations with immunoinhibitor, immunostimulator, major histocompatibility complex (MHC) molecule, chemokine receptor, tumor mutation burden (TMB), and microsatellite instability (MSI) levels in bladder cancer (BLCA). The validation cohort for immunotherapy corroborated these findings and substantiated that ESCO2 could function as an autonomous prognostic biomarker and a promising target for cancer treatment via immunotherapy. In addition, in vitro experiments confirmed the role of ESCO2 in influencing the proliferation, invasion, and migration of BLCA cells.</p><p><strong>Conclusion: </strong>ESCO2 participates in regulating the immune infiltration and affecting the prognosis of patients in many cancers, especially in BLCA. ESCO2 may serve as a prognostic and immunotherapy biomarker in future treatment of human cancer.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-18"},"PeriodicalIF":2.5,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142625257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk for Second Primary Ovarian Cancer: A Large Population Based on Surveillance, Epidemiology, and End Results Database.","authors":"Haiyang Hu, Yangsheng Ren, Huixing Li, Tishuo Zhang, Lin Sun","doi":"10.1159/000542044","DOIUrl":"10.1159/000542044","url":null,"abstract":"<p><strong>Introduction: </strong>This study aims to evaluate the likelihood of developing a second primary ovarian cancer (OC) considering factors including age, race, and the types of initial malignancies encountered.</p><p><strong>Methods: </strong>This study employed a retrospective cohort approach, compiling data on individuals diagnosed with OC from the Surveillance, Epidemiology, and End Results (SEER) program databases spanning the years 1975-2019. The analysis used standardized incidence ratios (SIRs) with 95% confidence intervals (CIs) to determine the likelihood of developing OC. The result was further refined by categorizing the data based on patient age, race background, first primary cancer types, the time elapsed since the second primary cancer diagnosis, and radiotherapy treatment.</p><p><strong>Results: </strong>A total of 1,536,151 patients with second primary cancer being OC were included. The SIR of the second primary OC was observed to be elevated among patients between the ages of 18-64 years (SIR: 1.09, 95% CI: 1.06-1.13). In contrast, for patients who were 65 years of age or older, the SIR for a second primary OC was found to be relatively lower (SIR: 0.87, 95% CI: 0.83-0.91). A lowering, however, not statistically significant, of the SIR of the second primary OC in patients with white race was presented. Within 2 months to 1-year diagnosis interval, the SIR of the second primary OC was highest (SIR: 1.48, 95% CI: 1.37-1.61). Liver, gallbladder, intrahepatic, and other bile ducts (SIR: 2.00, 95% CI: 1.38-2.81), and breast cancer (SIR: 1.20, 95% CI: 1.15-1.25) had higher SIRs of second primary OC.</p><p><strong>Conclusion: </strong>This study identifies age, ethnicity, the time span between the diagnoses, and the types of initial cancers as factors correlated with the occurrence of a second primary OC. Our findings suggest that targeted surveillance should be considered for high-risk groups.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-12"},"PeriodicalIF":2.5,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142625144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic and Immunotherapeutic Role of TACC3 in Pancancer and Its Impact on Proliferation and Docetaxel Resistance in Lung Adenocarcinoma.","authors":"Jianyu Xu, Ying Zhu, Qian Liu, Chenchang Xu, Wenjuan Wang, Jiantong Sun, Xinyuan Ding, Biao Liu, Lei Chen","doi":"10.1159/000542450","DOIUrl":"10.1159/000542450","url":null,"abstract":"<p><strong>Introduction: </strong>Transforming acidic coiled-coil containing protein 3 (TACC3) exerts a vital role in cancer progression by modulating cell division and facilitating tumor growth. Given the lack of comprehensive research on the pancancer implications of TACC3, our study aimed to analyze the functional role of TACC3 in pancancer and validate it through experimental investigations in lung adenocarcinoma.</p><p><strong>Methods: </strong>We first employed various bioinformatics techniques to investigate the expression and prognostic significance of TACC3 in pancancer. Subsequently, we analyzed the correlation between TACC3 and immune infiltration, immune checkpoints, drug sensitivity, as well as the prediction of immune therapy response. Finally, we validated the association between TACC3 and the proliferation of lung adenocarcinoma, as well as its resistance to docetaxel, through in vitro experiments.</p><p><strong>Results: </strong>Here, TACC3 exhibited high expression in human cancers and was associated with poor prognosis in various cancer types. It was also involved in immune infiltration and demonstrated a strong predictive ability for immune therapy response. Through drug sensitivity prediction, we further identified a potential association between TACC3 and docetaxel resistance, which was subsequently validated in lung adenocarcinoma.</p><p><strong>Conclusion: </strong>Our investigation of TACC3 revealed its potential as a promising target both for immunosuppression and docetaxel resistance in pancancer, especially in lung adenocarcinoma.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-16"},"PeriodicalIF":2.5,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142605427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}